PPD establishes Rare Disease and Pediatric Center of Excellence


WILMINGTON, NC (WWAY) — On Rare Disease Day, Pharmaceutical Product Development announced it has created a Rare Disease and Pediatric Center of Excellence to oversee all rare disease and pediatric-related drug development activities.

Rare Disease Day is observed on the last day of February each year to raise awareness of rare diseases.

According to a news release, a disease is designated as rare in the United States when it affects fewer than 200,000 people, in Europe when it affects no more than five in 10,000 people and in Japan when it affects fewer than 50,000 people. In the U.S. and Europe alone, as many as 60 million individuals are affected by one of the more than 6,000 identified rare diseases.

PPD’s new center of excellence provides pharmaceutical and biotechnology clients with a team of professionals focused on the design and execution of clinical trials that address the unique strategic, operational, medical and scientific challenges of clinical studies in rare disease and pediatric patient populations.

“Our new center of excellence builds on PPD’s longstanding expertise and experience to address the special drug development considerations of rare diseases and pediatrics,” said Karen Kaucic, M.D., PPD senior vice president and head of the center of excellence. “Our clients can depend on us for the latest trial design innovations, the ability to navigate complex trial logistics and our keen understanding of customized patient access strategies in low-prevalence, widely dispersed patient populations. We felt today was an appropriate time to introduce this new venture, as we join with the drug development community in recognizing Rare Disease Day.”

PPD says its team members in the center of excellence are seasoned pharmaceutical and clinical research professionals who have hands-on experience with rare diseases and pediatrics. The team is focused on addressing the specific challenges presented by the small, widely dispersed populations of rare disease and pediatric patients.

PPD’s particular expertise in rare diseases stems from having conducted more than 220 studies with more than 50,000 patients over the past five years.

PPD says it’s a leading clinical researcher in pediatric drug development, having conducted more than 400 clinical trials during the past five years, enrolling more than 97,000 patients across a wide range of therapeutic indications, including infectious diseases, respiratory, cardiology, oncology and immunology.

 

Categories: Local, New Hanover

Leave a Reply

Your email address will not be published. Required fields are marked *